Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events-Reference-Cited by-同舟云学术

Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events

Published:2014-03 Issue:3 Volume:275 Page:244-256
ISSN:0041-008X
Container-title:Toxicology and Applied Pharmacology
language:en
Short-container-title:Toxicology and Applied Pharmacology

Author:

Zeng Ke-Wu,Wang Shu,Dong Xin,Jiang Yong,Jin Hong-Wei,Tu Peng-Fei

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference40 articles.

1. Signal transducer and activator of transcription-3, inflammation, and cancer;Aggarwal;Ann. N. Y. Acad. Sci.,2009

2. Cytokine signal transduction and the JAK family of protein tyrosine kinases;Andrew;Bioessays,1994

3. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling;Beitz;J. Biol. Chem.,1999

4. Review: activation patterns of microglia and their identification in the human brain;Boche;Neuropathol. Appl. Neurobiol.,2013

5. The macrophage response towards LPS and its control through the p38MAPK–STAT3 axis;Bode;Cell. Signal.,2012

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JE-133 Suppresses LPS-Induced Neuroinflammation Associated with the Regulation of JAK/STAT and Nrf2 Signaling Pathways;ACS Chemical Neuroscience;2024-01-05

2. Network pharmacology to explore the mechanism of scutellarin in the treatment of brain ischaemia and experimental verification of JAK2/STAT3 signalling pathway;Scientific Reports;2023-05-09

3. Sesquiterpenoids from the sunflower family as potential anti-inflammatory candidates: a review;Acta Materia Medica;2023

4. Pharmacology of inhibitors of Janus kinases – Part 1: Pharmacokinetics;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2022-11

5. Pharmakologie der Januskinase‐Inhibitoren – Teil 1: Pharmakokinetik;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2022-11